Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119601) titled 'Impact of Ursodeoxycholic Acid on Clinical Outcomes in Patients with Acute Pancreatitis: A Randomized Controlled Trial' on Feb. 28.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First Affiliated Hospital of Nanchang University
Condition:
Acute pancreatitis
Intervention:
Ursodeoxycholic acid (Ursofalk) group:In addition to conventional therapy, ursodeoxycholic acid 250 mg was taken orally three times daily after meals for 4 weeks
if the hospital stay was shorter than 4 weeks, treatment continued until the 4-week endpoint.
Recruitment Status: Not Recruiting
Phase: 1
Date ...